



Software for  
Business Intelligence

# BizInt Smart Charts

Patents & IP Sequences | Clinical Trials | Drug Pipelines

## Medical Devices: Insights from clinical trials, literature, and patents

DPHT Spring Meeting 2016 - Orlando, Florida

*Matt Eberle, Product Specialist, [matt.eberle@bizint.com](mailto:matt.eberle@bizint.com)*

April 5, 2016

[www.bizint.com](http://www.bizint.com)

# Why Not Drug Pipeline Databases?

Drug Pipeline databases cover **drugs**:

- “*Drug and cell-based products* are tracked across all therapeutic areas and throughout the entire development process, from discovery to launch.”
- “51,000+ *drug* monographs”
- “over 60,000 highly detailed and fully searchable *drug* profiles”

A handful of related records in pipeline sources

- Can give the appearance of coverage
- Focus still on the drug - drug delivery/formulation/diagnostic

# A device is not a drug

Drug Profile

## Everolimus

**Alternative Names:** **Absorb**; Afinitor; Afinitor Dispersible; Afinitor; Afinitor Disperz; Certican; Esprit BVS; Promus; Promus Element; Promus Premier; RAD; RAD-001; SDZ RAD; Synergy; Votubia; Xience nano; Xience Prime; Xience V; Xience Xpedition; Zortress

Latest Information Update: 04 Mar 2016

 » [Print Profile](#)

### At a glance

**Originator** Novartis; Universi  
**Developer** **Abbott Laborator**  
 Boston Scientific  
 Hannover Medica  
 National Cancer I  
 Medicine; Novarti  
 Collaboration; SC  
 California at San  
 Texas M. D. And  
**Class** Antineoplastics;

### everolimus

Snapshot	Highlight <input type="checkbox"/> Search Terms & Synonyms	< Previous	Next >
Latest Press Releases	<b>SNAPSHOT</b>		
Latest Event Transcripts	<b>Drug Name</b>	everolimus	
Broker Research Reports	<b>Other Drug Names</b>	Afinitor; Afinitor Disperz; Apinito; Certican; RAD-001; RAD-001A; RAD001C; SDZ-RAD; Votubia; Zortress everolimus	
Development Profile	<b>Originator Company</b>	<a href="#">Novartis AG</a>	
Literature Review	<b>Active Companies</b>	<a href="#">Novartis AG</a>	
Development Status	<b>Inactive Companies</b>		
Chemical Structures	<b>Highest Phase</b>	Launched	
Drug Names	<b>Active Indications</b>	Acute lymphoblastic leukemia; Advanced solid tumor; Angiomyolipoma; Astrocytoma; Bladder cancer; E tumor; Colorectal tumor; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Epilepsy; Esopha tumor; Glioma; Head and neck tumor; Heart transplant rejection; Kidney transplant rejection; Liver transp rejection; Lung transplant rejection; Macroglobulinemia; Medullary thyroid cancer; Metastatic breast can Metastatic renal cancer; Neuroendocrine tumor; Neurofibromatosis type I; Non-Hodgkin lymphoma; Non-small-cell lung cancer; Pancreatic endocrine tumor; Renal cell carcinoma; Solid tumor; Stomach tu Thyroid tumor; Transplant rejection; Uveal melanoma <a href="#">View Epidemiology in</a>	
Sales and Forecasts	<b>Inactive Indications</b>	Acute myelogenous leukemia; Age related macular degeneration; Autosomal dominant polycystic kidney disease; Endometrioid carcinoma; Fallopian tube cancer; Gastrointestinal stromal tumor; Genetic disor Hematological neoplasm; Hepatocellular carcinoma; Herpesvirus type 8 infection; Hodgkins disease; Hormone refractory prostate cancer; Inflammatory bowel disease; Lymphoma; Mantle cell lymphoma; Melanoma; Meningioma; Mesothelioma; Multiple myeloma; Ovary tumor; Pancreas tumor; Peritoneal tu Pulmonary fibrosis; Renal insufficiency; Rheumatoid arthritis; Sarcoma; Small-cell lung cancer; Tuberou sclerosis; Uterine cervix tumor; Uveitis <a href="#">View Epidemiology in</a>	
Clinical Trials	<b>Target-based Actions</b>	mTOR inhibitor; mTOR complex 1 inhibitor	
Deals and Patents			
SWOT Analysis			
Change History			
Sources			

# No Drug Pipeline, No Problem

## Clinical Trials

- What is the mix of trials by phase and status?
- Which companies have clinical stage programs?

## Literature

- Who are the key opinion leaders?
- What are the new developments?

## Patents

- What are the key companies?
- What novel technologies are they developing?

# BizInt Smart Charts takes your search results

Patents

Drug Pipelines

Clinical Trials

Sequences

The image displays a collage of overlapping document pages from BizInt Smart Charts, showing various drug profiles. Each page contains detailed information about a specific drug, including its name, accession number, last update date, and key characteristics. The profiles are organized into sections such as 'Drug Development (Phase Extended)', 'Properties', 'Mechanism of Action', and 'Route of Administration'. Each section includes a table with columns for 'Indication', 'Phase', 'Route', and 'Country'. The drugs shown include Pretium – laculis Bibendum, Toror Felis – Nunc, Etiam Mollis – Aenean, and Consectetur. The pages are layered, with some appearing more prominent than others, creating a sense of depth and showcasing the variety of data available in the platform.

# ...and automatically builds summary tables.

## Patents | Drug Pipelines | Clinical Trials | Sequences

Combining results from different databases.

### Pretium – Iaculis Bibendum

Last Update: 2012-11-17  
Accession Number: 0000756977

**Indications:** Praesent, Fusce, Mauris Pharetra  
**Therapeutic Class (WHO):** Quisque faucibus scelerisque  
**Therapeutic Class (ATC):** Nulam pelleferentium

Indication	Phase	Route	Country
Praesent	Phase II	OP	Mauris
Fusce	Phase I	OP	Pharetra
Mauris Pharetra	Phase II	OP	Sedibus

### Toror Felis – Nunc

Last Update: 2011-06-03  
Accession Number: 000676411802

**Indications:** Congue, Sedibus  
**Therapeutic Class (WHO):** Quisque accumsan  
**Therapeutic Class (ATC):** Sullitudin

Indication	Phase	Route	Country
Congue	Phase II	OP	Quam
Sedibus	Phase II	OP	Sedibus

### Etiam Mollis – Aenean

Last Update: 2012-01-18  
Accession Number: 000089001002

**Indications:** Praesent, Bibendum, Libero  
**Therapeutic Class (WHO):** Donec, varius, augue  
**Therapeutic Class (ATC):** Nulam pelleferentium

Indication	Phase	Route	Country
Praesent	Phase 3	OP	Pharetra
Bibendum	Phase 2	OP	Pharetra
Libero	Phase II	OP	Pellentes

### Consectetur

Last Update: 2012-05-09  
Accession Number: 0005492961

**Indications:** Praesent, Fusce, Aenean  
**Therapeutic Class (WHO):** Quisque faucibus scelerisque  
**Therapeutic Class (ATC):** Nulam pelleferentium

Indication	Phase	Route	Country
Praesent	Phase II	OP	Quam
Fusce	Phase I	OP	Quam
Aenean	Phase 3	OP	Sedibus

	Drug	Common Drug Name	Database	Synoonyms	Highest Phase	Companies	Last Update
1		Pretium					
2	Pretium XGS	Pretium	Loareet Sem	Varius auctor Diam gravida XS-2	Phase2	Lobortis Turpis Egestas	2012-10-01
3	Sollicitudin 4S	Sollicitudin	Donec	Quam diam Augue diu	Phase 3	Egestas Conditumet Lobortis Turpis	2011-12-07
4	Sollicitudin	Sollicitudin	Elifend-UR	Quam diam Augue diu Ligula est lectus	Phase 3	Egestas Conditumet	2011-06-07
5	Etiam Mollis	Etiam Mollis	Loareet Sem	Adicing Proin Mattis Faucibus lacinula	Phase 3	Conditumet Eat	2012-01-13
6	Etiam Mollis	Etiam Mollis	Elifend-UR	Adicing Et Sec Proin Mattis Faucibus	Phase 2	Conditumet Eat	2012-01-13
7	Toror Felis	Toror Felis	Donec	Aenean lectus purus Nulla sit amet Quisque placenet 2A	Phase 2	Loareet	2011-06-03
8	Toror Felis III	Toror Felis	Loareet Sem	Aenean lectus purus Quisque placenet 2A	Phase 2	Loareet	2011-06-03
9	Consectetur	Consectetur	Donec	Purus non luma Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01
10	Consectetur 2A	Consectetur	Nullam	Purus non luma Ligula est Quam sem ac	Phase 3	Lobortis turpis	2012-03-01

# And, helps you create visualizations.

Patents


Drug Pipelines

Clinical Trials

Sequences

Collage of drug development documents including:

- Pretium – laculis Bibendum** (adipiscing elit)  
Last Update: 2012-11-17  
Accession Number: 00205768077  
Indications: Phasidus, Fucus, Mearis Phasidus  
Therapeutic Class (WHO): Curvus Mearis laculis-bibid  
Therapeutic Class (EMA): Nullum perferreque  
Originator: (originae condendum curvula (secundum))  
Other Companies: Liboribus torpis (sed adipiscit)  
Last Update: 2012-11-17  
Accession Number: 00205768077  
Confidence Rating: Aniparibus  
Higet Phase: Phasidus  
Drug Development (Phase Extended)  
Table with columns: Indication, Phase, Route, Country. Rows: Phasidus (Phase II, OP, Mearis), Fucus (Phase I, OP, Phasidus), Mearis Phasidus (Phase I, OP, Soddibus).
- Toror Felis – Nunc** (molestiae)  
Last Update: 2011-08-03  
Accession Number: 002075041902  
Indicators: Congrua Soddibus  
Therapeutic Class (WHO): Quia accumbent  
Therapeutic Class (EMA): Soddibus  
Originator: Liboribus (secundum)  
Other Companies: Liboribus (sed adipiscit)  
Last Update: 2011-08-03  
Accession Number: 002075041902  
Confidence Rating: Functibus  
Higet Phase: Phasidus  
Drug Development (Phase Extended)  
Table with columns: Indication, Phase, Route, Country. Rows: Congrua (Phase I, OP, Soddibus), Soddibus (Phase I, OP, Phasidus).
- Etiam Mollis – Aenean** (suscipit)  
Last Update: 2012-01-13  
Accession Number: 003480010403  
Indicators: Phasidus, Liboribus  
Therapeutic Class (WHO): Donec varius acuris  
Therapeutic Class (EMA): Nullum perferreque  
Originator: Phasidus laculis-bibid (secundum)  
Other Companies: Condendum (sed adipiscit)  
Last Update: 2012-01-13  
Accession Number: 003480010403  
Confidence Rating: Quisquam  
Higet Phase: Phasidus  
Drug Development (Phase Extended)  
Table with columns: Indication, Phase, Route, Country. Rows: Phasidus (Phase I, OP, Phasidus), Bibendum (Phase I, OP, Phasidus), Liboribus (Phase I, OP, Phasidus).
- Consectetur** (blanditiis)  
Last Update: 2012-05-01  
Accession Number: 00238693801  
Indicators: Phasidus, Fucus, Aenean  
Therapeutic Class (WHO): Vitibus laculis-bibid  
Therapeutic Class (EMA): Nullum perferreque  
Originator: (originae condendum curvula (secundum))  
Other Companies: Liboribus torpis (sed adipiscit)  
Last Update: 2012-05-01  
Accession Number: 00238693801  
Confidence Rating: Vitibus  
Higet Phase: Phasidus  
Drug Development (Phase Extended)  
Table with columns: Indication, Phase, Route, Country. Rows: Phasidus (Phase II, OP, Phasidus), Fucus (Phase I, OP, Phasidus), Aenean (Phase I, OP, Phasidus).



# BizInt Smart Charts

## *Reference Rows™*



- Information from related records is displayed in a **single “Reference Row”**.
- Based on **database rankings and rules**.
- A separate utility working with patent, drug pipeline, clinical trial, and sequence reports.
- *Included* in all BizInt Smart Charts licenses.



# VantagePoint - Smart Charts Edition

- Clean-up and filter your data.
- Create visualizations to add impact to your reports!
- Custom version of VantagePoint for use with BizInt Smart Charts.
- Add to your BizInt Smart Charts license.
- Sign up for a trial on our web site.



# Topic: Stents, **Bioresorbable Stents**

Tenekecioglu et al. *BMC Cardiovascular Disorders* (2016) 16:38  
DOI 10.1186/s12872-016-0207-5

BMC Cardiovascular Disorders

## REVIEW

Open Access

### Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention

JACC: CARDIOVASCULAR INTERVENTIONS  
© 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION  
PUBLISHED BY ELSEVIER INC.

<http://dx>

#### EDITORIAL COMMENT

### Bioresorbable Drug-Eluting Stents An Immature Technology in Need of Mature Application

Robert A. Byrne, MB, BC<sub>CA</sub>, PhD, Adnan Kastrati, MD

**B**ioresorbable coronary stents represent a breakthrough technology promising to enhance the outcomes of patients treated by percutaneous intervention (1). The benefits of bioresorbable stents are intuitive. Indeed, all else being equal, most physicians and patients would agree that a stent that disappears after its useful function is served would be a preferable device to a permanent metallic implant. Moreover, as suggested by recent

stents, the ABSORB stent may receive approval from the Food and Drug Administration by the end of 2016.

An important requirement for any new technology should be demonstration of superiority versus contemporary metallic stents in the initial phase after implantation (2). This is not an essential condition, for their advantages are for testing potential late benefit. U

## TOMORROW'S MEDICINE

### New Stent Leaves No Polymer Behind

Boston Scientific's Synergy stent is designed so the drug-eluting polymer breaks down. Are totally bioresorbable stents far behind?

Thomas Morrow, MD

**U**nless you are nearing Medicare age, you will not remember the exhilaration created by the introduction of the

neointimal hyperplasia that line the inside of the artery to infiltrate the stent through the


News Feature | May 18, 2015



### Scientists Incorporate Smart Technology into Bioresorbable Stents

By Suzanne Hodsdon

A research team in Korea has developed new innovations for bioresorbable stents by adding a host of biosensors that can track and store data, deliver drugs, and communicate with healthcare providers. This new technology is expected to overcome some of the



# Clinical Trials - challenges for devices

- Not all clinical trial sources cover devices.
- Not all devices require clinical trials.
- Device may not be listed as a Device in ClinicalTrials.gov, but as Procedure, Behavioral, Other.
- Device may be mentioned only in Outcomes or Inclusion/Exclusion Criteria.

# Which Clinical Trials sources...

## Include Medical Devices

- [ClinicalTrials.gov](http://ClinicalTrials.gov)
- Thomson Reuters Cortellis Clinical Trials Intelligence - "includes over 190,000 global trials, covering drugs, biologics, *medical devices* and biomarkers."
- Adis Clinical Trials Intelligence

# Which Clinical Trials sources...

## Exclude Medical Devices

- **EudraCT** - “The EU Clinical Trials Register does not: provide information on clinical trials for surgical procedures, *medical devices* or psychotherapeutic procedures”
- **TrialTrove** - Inclusion/Exclusion per indication. For Coronary Artery Disease, explicitly excluded are “Trials involving *drug-eluting stents*”


# Clinical Trials

- What is the mix of trials by phase and status?
- Which companies have clinical stage programs?

# Combine and Integrate Trial Records


	Trial Title	Acronym	Database	Phase	Overall Status	Start Date
100.	Bioabsorbable Vascular Solutions First in Man Clinical Investigation: A Clinical Evaluation of the Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients With Single de Novo Native Coronary Artery Lesions	ABSORB A	100.1 NCT   <a href="#">link</a>	Phase 3	Completed	March 2006
			100.2 ACT3   <a href="#">link</a>			
			100.3 CORTT   <a href="#">link</a>			
	100.1 NCT	100.1 NCT		100.1 NCT	100.1 NCT	100.1 NCT
101.	Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis	AbsorbISR	101.1 NCT   <a href="#">link</a>	Phase 3	Recruiting	March 2015
			101.2 ACT3   <a href="#">link</a>			
			101.3 CORTT   <a href="#">link</a>			
	101.1 NCT	101.1 NCT		101.1 NCT	101.1 NCT	101.1 NCT
102.	BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V	BIOFLOW-V	102.1 NCT   <a href="#">link</a>	Phase 3	Recruiting	May 2015
			102.2 ACT3   <a href="#">link</a>			
	102.1 NCT	102.1 NCT		102.1 NCT	102.1 NCT	102.1 NCT
103.	Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI)	BVS in STEMI	103.1 NCT   <a href="#">link</a>	Phase 3	Recruiting	August 2014
			103.2 CORTT   <a href="#">link</a>			
	103.1 NCT	103.1 NCT		103.1 NCT	103.1 NCT	103.1 NCT

# Trial Phase





# Trial Status




# How do you build it: standard charts

- **Clinical Trials** -Import and Combine from all sources.
- **Reference Rows** - Integrate to work with data from all sources as a unit.
- **VantagePoint - Smart Charts Edition (VP-SCE)**
  - Normalize phase and status terminology with built-in thesauri.
  - Create charts in VP-SCE or send normalized data to Excel or another charting tool.

# Trial Trends - Company by Trial Start

Bioresorbable stent trials by start date

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016



# Look for trends - building a bubble chart

- **Clinical Trials** - Import and Combine.
- **Reference Rows** - Integrate to work with data from all sources as a unit.
  
- **VP-SCE**
  - Cleanup company names.
    - Use fuzzy matching for faster cleanup.
    - Save cleanup as a thesaurus for future work.
  - Extract start year from trial start date.
  - Create the bubble chart.

# Which Literature sources...


## Biomedical databases

- MEDLINE®
- Embase®
- BIOSIS Previews®

# Literature

- Who are the key opinion leaders?
- What are the new developments?

# Look for Key Opinion Leaders




# Steps in building standard charts

- Literature - Import and Combine.
- Reference Rows - Integrate.
- VantagePoint - Smart Charts Edition (VP-SCE)
  - Cleanup author names.
    - Use fuzzy matching for faster cleanup.
    - Save cleanup as a thesaurus for future work.
  - Create charts in VP-SCE or send normalized data to Excel or another charting tool.



# Identify new developments



# Identify what's new

- BizInt Smart Charts - Import and Combine.
- VP-SCE
  - Extract year from publication date.
  - Automatically identify terms by first year.
  - Select years to focus on (2011-2016).
  - Create the bubble chart.
  - Review in VP-SCE or export back to BizInt Smart Charts to review the associated literature in more detail.

# Review the associated literature

Combined: Bioresorbable stents Medl Emb BIOSIS ProQuestDocuments-2016-03-24					
	Title	Author	Source	Publication Date	Chemical names last 5 yrs
2	Fe-Au and Fe-Ag composites as candidates for biodegradable stent materials	Huang, Tao Cheng, Jian Bian, Dong Zheng, Yufeng	Journal of Biomedical Materials Research - Part B Applied Biomaterials (Feb 1, 2016), vol. 104, no. 2, p. 225-240.	2016-02-01	gold silver
3	Biphasic responses of human vascular smooth muscle cells to magnesium ion	Ma, Jun Zhao, Nan Zhu, Donghui	Journal of Biomedical Materials Research - Part A (Feb 1, 2016), vol. 104, no. 2, p. 347-356.	2016-02-01	magnesium ion
4	Strength reliability and in vitro degradation of three-dimensional powder printed strontium-substituted magnesium phosphate scaffolds	Meininger, Susanne Mandal, Sourav Kumar, Alok Groll, Jürgen Basu, Bikramjit Gbureck, Uwe	Acta Biomaterialia (Feb 1, 2016), vol. 31, p. 401-411.	2016-02-01	magnesium ion
5	6-Month Follow-Up of a Novel Biodegradable Drug-Eluting Stent Composed of Poly-L-Lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery	Xiao, Jianmin Feng, Gaoke Kang, Guanyang Lan, Zhiyuan Liao, Tianshi Kislauskis, Edward Chen, Jiuhao Xia, Jinxi Wang, Zhimin Huo, Zhicheng Wang, Qun Xi, Tingfei McCarthy, Stephen Jiang, Xuejun Wu, Tim Laham, Roger	Journal of biomedical nanotechnology (Oct 2015), vol. 11, no. 10, p. 1819-25.	2015-10-01	Nanocapsules
6	Biodegradable Stent Platforms: Are We Heading in the Right Direction?	Lavi, Shahar D'Avila, Vladimir	Canadian Journal of Cardiology (Aug 1, 2015), vol. 31, no. 8, p. 957-959.	2015-08-01	gold
7	Effectiveness of Biodegradable Magnesium Alloy Stents in Coronary Artery and Femoral Artery	Yue, Yunan Wang, Lili Yang, Nuo Huang, Jinglin Lei, Licheng Ye, Huiming Ren, Lihui Yang, Shuixiang	Journal of Interventional Cardiology (Aug 1, 2015), vol. 28, no. 4, p. 358-364.	2015-08-01	aluminum zinc

# Which Patent sources...

- Thomson Reuters Cortellis
- PatBase
- LifeQuest

# Patents


- What are the key companies?
- What novel technologies are they developing?



# Look for trends - building a bubble chart

- **Patents** - Import and Combine from all sources.
- **Reference Rows** - Integrate to work with data from all sources as a unit.
- **VP-SCE**
  - Cleanup company names.
    - Use fuzzy matching for faster cleanup.
    - Save cleanup as a thesaurus for future work.
  - Extract priority year from priority date.
  - Create the bubble chart.

# Classification codes unique to top assignees





# Differentiate top companies

- **Patents** - Import and Combine from all sources.
- **Reference Rows** - Integrate.
- **VP-SCE**
  - Cleanup company names.
  - Select top companies to focus on.
  - Automatically identify IPC codes unique to a single top assignee.
  - Create the Aduna cluster map.
  - Review in VP-SCE or export back to BizInt Smart Charts.

# Classification codes unique to top assignees

	Title	Database	Original Assignee	Priority Date	IPCs unique among top assignees
1.	THIN STRUT STENT FROM BIOABSORBABLE POLYMER WITH HIGH FATIGUE AND RADIAL STRENGTH AND METHOD TO MANUFACTURE THEREOF	1.1 Patbase   <a href="#">link</a>	MERIL LIFE SCIENCES PVT LTD	2014-07-07	B21D39
		1.1 Patbase		1.1 Patbase	1.1 Patbase
2.	The short pulse laser machining which is improved using the light absorbing agent for manufacturing the medical device like the stent of the polymer.	2.1 CORTP   <a href="#">link</a> 2.2 Patbase   <a href="#">link</a>	Abbott Cardiovascular Systems Inc.	2013-03-13	B23K35
		2.1 CORTP		2.1 CORTP	2.1 CORTP
3.	Laser cut intraluminal medical devices	3.1 CORTP   <a href="#">link</a> 3.2 Patbase   <a href="#">link</a>	Cordis Corporation	2005-12-15	B23K6
		3.1 CORTP		3.1 CORTP	3.1 CORTP
4.	Micro-structured and nano-structured surfaces on biodegradable polymers	4.1 LIFEQ   <a href="#">link</a>	NANYANG TECHNOLOGICAL UNIVERSITY	2005-07-06	B27N3
		4.1 LIFEQ		4.1 LIFEQ	4.1 LIFEQ
5.	BIOMIMETIC SCAFFOLDS	5.1 Patbase   <a href="#">link</a> 5.2 LIFEQ   <a href="#">link</a>	HASHI CRAIG HUANG NGAN FONG KURPINSKI KYLE LI SONG PATEL SHYAM UNIV CALIFORNIA	2006-01-27	B27N3
		5.1 Patbase		5.1 Patbase	5.1 Patbase
6.	Bioabsorbable stent with layers having different degradation rates	6.1 CORTP   <a href="#">link</a> 6.2 Patbase   <a href="#">link</a>	Abbott Cardiovascular Systems Inc.	2008-02-25	B28B11 B29C37
		6.1 CORTP		6.1 CORTP	6.1 CORTP



Software for  
Business Intelligence

# BizInt Smart Charts

Talk to me at the  
meeting or contact us:  
[support@bizint.com](mailto:support@bizint.com)  
[www.bizint.com](http://www.bizint.com)

[bizint.com/slides](http://bizint.com/slides)